TITLE

An inconspicuous insect bite as the cause of sepsis in a patient treated with infliximab due to rheumatoid arthritis

AUTHOR(S)
Zynek-Litwin, M.; Kuźniar, J.; Noceń-Rychlewska, B.; Kusztal, M.; Klinger, M.
PUB. DATE
June 2011
SOURCE
Advances in Medical Sciences (De Gruyter Open);2011, Vol. 56 Issue 1, p106
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The monoclonal antibody against TNFa (infliximab) suppresses cytokines involved in inflammatory reaction. Consequently, infliximab is a potent agent in treating refractory rheumatoid arthritis (RA). There is also evidence showing beneficial anti-TNFα therapy effect on RA-related amyloidosis AA. TNFα inhibition may, however, lead to leucopenia and, eventually, severe sepsis. We discuss a case of RA with RA-related AA amyloidosis and renal impairment which was refractory to disease-modifying anti-rheumatic drug (DMARD). The treatment led to inflammatory complications of two distinct phases: immediately after drug administration and six weeks later. Both phases were linked to an innocuous skin infection.
ACCESSION #
61031868

 

Related Articles

  • infliximab.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1190 

    A reference entry for "infliximab" which refers to an antibody against tumor necrosis factor is presented.

  • Infliximab: A Review of its Use in the Management of Rheumatoid Arthritis. Markham, A.; Lamb, H.M. // Drugs;Jun2000, Vol. 59 Issue 6, p1341 

    Infliximab is a chimaeric monoclonal antibody to human tumour necrosis factor-α (TNFα). It binds to both soluble and transmembrane forms of TNFα at picomolar concentrations in vitro. Secondary to inhibition of TNFα, infliximab reduces serum levels of inflammatory mediators and...

  • Infliximab, non-melanoma skin cancers: Australian update.  // Reactions Weekly;Aug2015, Vol. 1565 Issue 1, p3 

    The article reports that the Therapeutic Goods Administration (TGA) has announced that the product information for infliximab, a monoclonal antibody, has been updated in Australia.

  • Study May Explain Racial Disparity in CKD Patients.  // Renal & Urology News;Jun2010, Vol. 9 Issue 6, p42 

    The article reports on the findings of a study regarding the racial disparity in patients with chronic kidney disease (CKD) in the U.S.

  • Tissue transplantation.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS105 

    Presents an abstract of the research manuscript `Identification of risk factors for diminished renal function 2 years post transplant,' by P. Nickerson et al.

  • Series on nursing pharmacology and medicine management Part 6: Practical aspects of drug administration: biotechnology drugs. Schellack, G. // Professional Nursing Today;2012, Vol. 16 Issue 6, p20 

    In this, the sixth in a series of articles on practice-related aspects of pharmacology, drug therapy, and applied nursing pharmacology, we will examine novel advances in drug therapy, with specific reference to biotechnology drugs and monoclonal antibodies. This series uses permitted excerpts...

  • A Review of the Use of Infliximab to Manage Cutaneous Dermatoses. Gupta, Aditya K.; Skinner, Alayne R. // Journal of Cutaneous Medicine & Surgery;Mar/Apr2004, Vol. 8 Issue 2, p77 

    Background: Infliximab is a chimeric monoclonal antibody that binds specifically to human tumor necrosis factor-alpha (TNF-α), decreasing the effect of the cytokine in inflammatory diseases. Objective: The aim of this study was to review the efficacy and safety of infliximab in the treatment...

  • Administration of Infliximab in Crohn's Disease Does Not Deplete Complement Components C3 and C4. Arnott, Ian D. R.; Shand, Alan; Ghosh, Subrata // American Journal of Gastroenterology;Nov2000, Vol. 95 Issue 11, p3326 

    Assesses whether there is any evidence of complement consumption in Crohn's disease patients undergoing treatment with infliximab. Efficacy of infliximab in treating the disease; Changes in complement fractions following treatment with a single infusion of infliximab.

  • Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Erckens, R.; Mostard, R.; Wijnen, P.; Schouten, J.; Drent, M. // Graefe's Archive of Clinical & Experimental Ophthalmology;May2012, Vol. 250 Issue 5, p713 

    Introduction: Adalimumab, a humanized monoclonal antibody targeted against TNF-α, has proved to be successful in the treatment of uveitis. Another anti-TNF-α agent, i.e., infliximab, has been reported of benefit in the treatment of refractory sarcoidosis. The aim of this prospective case...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics